TAPIMMUNE

www.tapimmune.com
OTCBB: TPIV

Cautionary Statement Regarding Forward Looking Statements

Certain statements contained herein are forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this document include, but are not limited to, statements relating to long-term stability, the Company's plan of operations and finances, the potential for the Company's vaccines and proposed clinical trials.

The reader is cautioned that any such forward-looking statements are not guarantees of future performance and that actual results may differ materially from estimates in the forward-looking statements. The Company undertakes no obligation to revise these forward-looking statements to reflect events or circumstances after the date hereof.

TAPIMMUNE

"Immunotherapies for Cancer, Infectious Disease and Bio-Defence"

Corporate Profile

- TapImmune Inc. is a biotechnology company specializing in the development of innovative therapeutics and vaccines in the areas of oncology and infectious disease.
- Technology discovery at University of British Columbia
- Public corporation trading on OTCBB (TPIV)
- Based in Seattle, WA

Media Coverage

Market for Immunotherapies/Vaccines

- Fastest growing segment of pharmaceutical market:
- The global vaccine market is expected to grow to $23 billion in 2011
  - Cancer:
    - Projected $10 billion U.S. for cancer vaccines with CAGR of 70-100%
    - Stimulated by recent approvals of Dendreon's Provenge and BMS Yervoy
  - Infectious Disease:
    - Projected market - $12 billion
    - Viral pandemics, societal pathogens, bio-defense

What is "TAP"?

Transporters associated with Antigen Presentation

- TAP is a 'Protein Pump' responsible for shuttling antigens to the surface of cells for presentation to the immune system
- Cancer cells turn TAP 'OFF' effectively hiding the cancer cells from the immune system
- Simply put, we turn TAP 'ON' again making the rogue cells visible to the immune system so they can be targeted and destroyed.
- The same process or 'switch' makes infectious disease vaccines significantly more effective or potent
- This means increased productivity, lower cost and possible lower side effects

TAP Technology Platform

- TAP is a KEY component in immune recognition pathway
- Stimulates T-cell recognition of antigens and production of cytotoxic T-cells that can infiltrate and kill tumors
- TAP is restored or up-regulated by delivering the genetic code to cells by a viral vector
- TAP then facilitates the binding of the foreign peptides to the MHC class I complex
- These are subsequently displayed on the infected cell's surface.
- Cytotoxic T-Cells recognize foreign peptides bound to the MHC class I antigen on the cell surface and destroy infected cells

TAP treatment Restores Immune Recognition in Cancer





- Tumor cells now visible to the immune system
- Tumor cells unmasked by TAP immune system now targets for them for destruction

Need to Augment TAP levels in Infectious Disease

- Viral infections produce a range of viral peptides that may “overwhelm” normal TAP system
- Results in insufficient viral antigens presented to the cellular immune system
- Diminished expression of TAP is associated with disease susceptibility
- TapImmune vectors augmenting normal TAP levels boost immunity and greatly improve vaccine efficacy
- TAP study showed that adding TAP to a POX vaccine made the vaccine 100-1000 times more effective

TAP Enhances Immune Recognition in Infectious Disease





- Greater number of viral antigens visible to the immune system
- Increases efficacy of studied vaccine by up to 1000 times
- Greater productivity makes vaccine available to more people at lower cost
- *'Major step forward in new vaccine development'* Plos Pathogen

Efficacy of TAP vector technology

- Cancer:
  - Mouse models of metastatic melanoma and small cell lung cancer:
    - Reduced metastasis
    - Higher survival
- Infectious Disease:
  - 100-1000 fold increase in efficacy of smallpox vaccine in animals.

Clinical Development

MAYO CLINIC Phase 1
HER2/neu +ve Breast Cancer Vaccine

- Combination of TAP + HER2/neu antigens – Mayo Clinic
  - applicable to ~ 80% of HER2/neu +ve patients
  - IND for Phase I studies approved July '11
  - Sponsored Research Agreement with Mayo Clinic Signed Aug '11
  - Clinical Trial Begins Oct 2011 on HER2/neu +ve patients

- Current therapy:
  - Trastuzumab (Herceptin) over $5billion in annual sales
  - applicable to ONLY ~ 30% of HER2/neu +ve patients

Research
Smallpox/Biodefense Vaccines

- TAP improved potency of smallpox vaccine by 100-1000 fold
- MAYO CLINIC Collaboration in Smallpox underway
- TAP + peptide antigens licensed from Mayo Clinic
  - Broader patient population; cheaper, longer shelf-life
- "Animal Efficacy Rule" FDA pathway (24-36 months to potential stockpiling)
- Potential for TAP vaccine to be stockpiled for variety of emerging bio-threats, e.g. Dengue

Peer Reviewd Journal Publications

Pharma Mag March 2011

- Novel Targets for Cancer Vaccine Development

International Journal of Cancer: 120 (1935-1941) 2007

- TAP expression reduces IL-10 expressing tumor infiltrating lymphocytes and restores immunosurveillance against melanoma

Science Direct: Vaccine: 25 (2331-2339) 2007

- Tumour immunity and T cell memory are induced by low dose inoculation with a non-replicating adenovirus encoding TAP1

PLoS Pathogens: Volume 1 (Issue 4/ e36) December 2005

- Using the TAP Component of the Antigen-Processing Machinery as a Molecular Adjuvant

Cancer Research 65 (7926-7933) September 1, 2005

- Restoration of the Expression of Transporters Associated with Antigen Processing in Lung Carcinoma Increases Tumor-Specific Immune Responses and Survival

Cancer Research 16 (7485-7492) August 15, 2005

- Identification of Mechanisms Underlying Transporter Associated with Antigen Processing Deficiency in Metastatic Murine Carcinomas

Journal of Immunology 172 (5200-5205) May 2004

- CTL-Dependent and -Independent Antitumor Immunity Is Determined by the Tumor Not the Vaccine

Nature Biotechnology 18 (515-520), May 2000

- TAP expression provides a general method for improving the recognition of malignant cells in vivo

Patents

- METHOD OF IDENTIFYING MHC-CLASS I RESTRICTED ANTIGENS
- METHOD OF ENHANCING EXPRESSION OF AN IMMUNE REPSONSE
- LOW DOSE INNOCULATION WITH TAP-I FOR ANTITUMOR IMMUNITY
- HAT ACETYLATION PROMOTERS
- POXVIRADAE TREATMENT
- COMBINATION OF ANTIGEN PROCESSING COMPONENTS ELICITS SURVIVAL IN TUMOR-BEARING ANIMALS
  - Patents issued in multiple global jurisdictions as recent as Aug 2011

Leverage of Collaborations

- Crucell NV
  - TAP manufacturing (PerC6)
- Aeras (Global TB Vaccine Foundation)
  - TB antigens (Phase II clinical) + TAP
  - New TB vaccine including TAP
- Mayo Clinic:
  - Cancer: HER2/neu +ve breast cancer antigen technology
  - Bio-Defence: Smallpox virus antigen technology

Management

- **Glynn Wilson, Ph.D.**
  Executive Chairman and CEO
  Head of Drug Delivery at SmithKline Beecham Pharmaceuticals, Research Area Head in Advanced Drug Delivery at Ciba-Geigy Pharmaceuticals, and President and co-founder of Auriga Pharmaceuticals, Executive Vice President of R&D at Tacora Ph.D. in Biochemistry and conducted medical research at The Rockefeller University, New York. He has been on the Board of TapImmune for 4 years.

- **Denis D Corin (B.Soc.Sci)**
  President and CFO
  Denis Corin served as TapImmune's President and CEO from Nov 2006 to July 1st 2009. He is a management consultant with experience in large pharmaceutical (Novartis), diagnostic instrumentation companies (Beckman Coulter) as well as the small cap biotech arena (MIV Therapeutics). He holds a double major Bachelors degree in Economics and Marketing from the University of Natal, South Africa.

Advisors and R&D Team

- Mac Cheever (Corixa; Fred Hutchinson Cancer Center)
- Mark Reddish (Biomira; ID Biomedical)
- Keith Knutson (Mayo Clinic)
- Greg Poland (Mayo Clinic)
- Lynn Depippo (Sherbrook Capital Management)

Our Vision for TAP

- Leading Immunotherapy Company
- Multiple technologies
- Fight against cancer:
  - Multiple metastatic cancers
  - Multiple combination products
  - Early stage prophylactic use
- Stockpiled for biodefense threats and viral pandemics:
  - Variety of infectious diseases
  - Emerging bio-terrorist threats
  - Making other vaccines more effective

Investors that Share our Vision
Why Invest in TPIV now?

- Breakthrough technology
- Strong product pipeline
- World-class team and collaborators
- Risk diversification – cancer & infectious disease
- Compelling preclinical data
- Start of clinical programs
- **Undervalued and poised for significant growth**

TAPIMMUNE